Pregnancy RelatedEarly Phase 1uSI-rangesNCT04548453
Establish the uSI Values and End-user Training Material That Will be Used to Guide Oxytocin Dosing Actions
A Early Phase 1 study testing uterine electromyography in people with Pregnancy Related and Labor Long, run by PreTeL, Inc at 1 site in United States.
Trial summary
Patients receiving oxytocin for induction or augmentation of labor will be studied with uterine EMG. The results of the EMG will be converted to an oxytocin-associated uterine stimulation index (uSI), which is intended to guide decisions for changing the dose of oxytocin. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pregnancy Related, Labor Long, Fetal Distress
- What is being tested?
- uterine electromyography
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 51 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2021to Oct 2021
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18 or greater
- At least 37 weeks gestation
- English reading and speaking
- Female gender
- Singleton fetus
- Planned continuous external fetal monitoring: to include fetal heart rate and uterine contraction monitoring
Show all 14Show fewer
- May have clinical indications for internal monitoring (IUPC and/or FSE) that replaces external monitoring.
- Induction or augmentation of labor with oxytocin (Pitocin)
- Subjects undergoing artificial rupture of membranes (AROM) or who experienced spontaneous rupture of membranes (SROM), with a plan for oxytocin administration, will be included as a special category.
- Subjects may undergo cervical ripening.
- Patients must be able to review and sign informed consent to participate in the study.
- Trial of labor after Cesarean section are eligible for participation
- Women diagnosed with diabetes and/or pre-eclampsia with or without magnesium therapy are eligible for participation
- Women with other complications of pregnancy are eligible for participation if the complication does not interfere with fetal monitoring, EMG monitoring or other recording of data.
Who cannot join
- Non-English reading and/or speaking
- Twins, triplets and other multifetal gestations
- Non-vertex presentation
- Planned Cesarean delivery
- Significant uterine anomalies such as didelphys or bicornuate uterus (women with small, clinically insignificant anomalies such as uterine fibroids are not excluded).
- Participants cannot be participating in any other research study or protocol regarding uterine contraction monitoring during the same study period as required for our study.
Show all 11Show fewer
- Known allergy to ECG pad adhesive
- Non-living fetus
- Major fetal malformation
- Fetal distress, or other indications for emergent delivery
- Other than a Category I fetal heart tracing at the beginning of the recording.
Trial locations and contacts
1 site in 1 country.
About this study
Patients receiving oxytocin for induction or augmentation of labor will be studied with uterine EMG. The results of the EMG will be converted to an oxytocin-associated uterine stimulation index (uSI), which is intended to guide decisions for changing the dose of oxytocin. An expert panel will review the results of the oxytocin dosing actions, then assigned optimized actions throughout the labor. The uSI will be correlated with the optimal dosing actions.
Read the detailed description
Background. Oxytocin stimulates the uterus, increases the strength and frequency of uterine contractions and facilitates delivery. The "dose" of oxytocin is the rate of IV infusion. In a typical labor where oxytocin is used, many dosing adjustments are performed over many hours. Finding the correct dose for a given patient is challenging because some women respond rapidly to low doses of oxytocin, others require high doses. The correct dose is important because the risks of adverse outcomes increase when doses are either too low or excessive. The dosing actions increase, hold, decrease or stop are typically performed every 30 minutes during oxytocin administration.
Dosing actions are performed based on the current level of simulation caused by the current dose. To assess the level of stimulation, current methods rely heavily on the output of the fetal monitor, which produces contraction frequency and fetal heart rate. Additional information for dosing decisions is obtained from subjective assessments such uterine palpation. Subjective measures are used because there is no objective method available to reliably guide a dosing action. Subjectivity is a major contributor to the long duration of labor for inductions and the high rate of excessive uterine stimulation with any oxytocin use.
The uterine stimulation index (uSI) is an objective measure of the current level of stimulation caused by the current dose of oxytocin in individual patients and can be used to guide oxytocin dosing actions. uSI is based on an electromyography (EMG) signal that is proportional to the effects of oxytocin on the uterine muscle. uSI is calculated from multichannel EMG to obtain a representative sampling of the effects of oxytocin on entire uterus. The range of values for uSI is from 0 (no oxytocin effects) to 10 (maximal oxytocin effects). Low values of uSI guide the end-user to increase the current dose of oxytocin. Intermediate values of uSI guide the end-user to hold the current dose. High values of uSI guide the end-user to decrease the current dose.
The purpose of this study is to establish the ranges of uSI values that correspond to the dosing actions increase, hold and decrease. To establish these ranges, 51 subjects will undergo current methods of dosing while having multichannel EMG recorded. uSI values will not be available to end-users, so all subjects will receive dosing actions determined by standard of care using current method. After delivery, a panel of experts will retrospectively assess each dosing action based on the outcome of the dosing action. These "optimized dosing actions" will then be correlated with the uSI value obtained at that time. This process produces paired data of optimized actions and uSI values. From the clustering of the uSI values, the ranges of uSI can be matched to the dosing actions increase, hold and decrease.
As a second goal, human factors will be studied with questionnaires and end-user interviews to improve the methods used for recording multichannel EMG during labor.
Procedure. Patients receiving oxytocin for clinical indications will be approached for participation. After obtaining consent, up to 8 proprietary EMG sensors will be placed over the subject's abdomen, spanning most of the surface of the uterus. Additionally, one ground sensor and one noise rejection sensor will be placed. Multichannel EMG recordings will be obtained throughout the labor, although the results of the EMG will not be available to the obstetrical providers. Subjects will be managed using current methods of monitoring and standard of care for oxytocin dosing decisions.
At the conclusion of the recording, the EMG sensors will be removed from the subject. Data will be analyzed after delivery, producing uSI values as a function of time for the duration of the labor.
An expert panel will be assembled, composed of clinicians trained in the art of obstetrics and managing oxytocin. The progress of labor will be assessed by examining the fetal monitor strip (i.e. uterine contractile activity and the fetal heart rate over time), cervical changes, and the dosing actions performed. No less than 72 hours after delivery the neonate's and subject's medical records will be reviewed to identify complications of the delivery that may have occurred.
The expert panel will assess each dosing action as optimal or not optimal. An example of a not optimal action would be increasing the dose and causing uterine tachysytole. In this example, "hold" will be assigned as the optimized dosing action. Each subject will have a list of optimized dosing actions and the time they were performed. Optimized dosing actions will then be linked with uSI values observed at that time, creating a paired data set of uSI values and optimal dosing actions.
The optimized dosing actions increase, hold and decrease will be correlated with uSI values and the range of uSI values that correspond with each dosing action will be established.
End-users will be interviewed 1 to 72 hours after delivery of the baby. The interview will identify barriers to EMG recording may influence the effectiveness of the information provided by the multichannel EMG recording.
- Conditions
- Pregnancy Related, Labor Long, Fetal Distress
- Being tested
- uterine electromyography
- Keywords
- labor, oxytocin, tachysystole, prolonged labor
- Medical subject headings
- Fetal Distress
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
uterine electromyographyDevice
Also called electrohysterography
Multichannel uterine electromyography will record uterine biosignals during labor.
| Study group | Role | What they receive |
|---|---|---|
| Uterine EMG during labor | Experimental | Multichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor. Receives: Device: uterine electromyography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlating uSI with the optimized dosing actions increase, hold and decrease
uSI clustering with dosing actions will be identified to provide guidance when prospectively dosing oxytocin
Measured: 8 months
Human factors in recording multichannel EMG during labor
Difficulties and discomfort of the EMG recording process will be identified and corrected
Measured: 8 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2020
- Study startApr 2021 (estimated)
- Primary completionOct 2021 (estimated)
- Study completionOct 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pregnancy RelatedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- prospective, non-significant risk
- Masking
- None (open label)
- Enrolment
- 51 participants (estimated)
Sponsor and investigators
- Lead sponsor
- PreTeL, Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04548453
- Sponsor's protocol ID
- uSI range setting study
- Acronym
- uSI-ranges
- Status last verified
- Sep 2020
- First submitted
- 1 Sep 2020
- Last updated
- 14 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: No IPD will be shared with other researchers. Data in summary form, based on numerical assessments of the uSI and optimized dosing actions will be published.
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establish the uSI Values and End-user Training Material That Will be Used to Guide Oxytocin Dosing Actions
- ClinicalTrials.gov ID
- NCT04548453
- Acronym / sponsor ID
- uSI-ranges / uSI range setting study
- Conditions
- Pregnancy Related, Labor Long, Fetal Distress
- Keywords
- labor, oxytocin, tachysystole, prolonged labor
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 51 participants (estimated)
- Lead sponsor
- PreTeL, IncIndustry (pharma, biotech, devices)
- Study start
- Apr 2021 (estimated)
- Primary completion
- Oct 2021 (estimated)
- Study completion
- Oct 2021 (estimated)
- First posted
- 14 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients receiving oxytocin for induction or augmentation of labor will be studied with uterine EMG. The results of the EMG will be converted to an oxytocin-associated uterine stimulation index (uSI), which is intended to guide decisions for changing the dose of oxytocin. An expert panel will review the results of the oxytocin dosing actions, then assigned optimized actions throughout the labor. The uSI will be correlated with the optimal dosing actions.
Detailed description
Background. Oxytocin stimulates the uterus, increases the strength and frequency of uterine contractions and facilitates delivery. The "dose" of oxytocin is the rate of IV infusion. In a typical labor where oxytocin is used, many dosing adjustments are performed over many hours. Finding the correct dose for a given patient is challenging because some women respond rapidly to low doses of oxytocin, others require high doses. The correct dose is important because the risks of adverse outcomes increase when doses are either too low or excessive. The dosing actions increase, hold, decrease or stop are typically performed every 30 minutes during oxytocin administration.
Dosing actions are performed based on the current level of simulation caused by the current dose. To assess the level of stimulation, current methods rely heavily on the output of the fetal monitor, which produces contraction frequency and fetal heart rate. Additional information for dosing decisions is obtained from subjective assessments such uterine palpation. Subjective measures are used because there is no objective method available to reliably guide a dosing action. Subjectivity is a major contributor to the long duration of labor for inductions and the high rate of excessive uterine stimulation with any oxytocin use.
The uterine stimulation index (uSI) is an objective measure of the current level of stimulation caused by the current dose of oxytocin in individual patients and can be used to guide oxytocin dosing actions. uSI is based on an electromyography (EMG) signal that is proportional to the effects of oxytocin on the uterine muscle. uSI is calculated from multichannel EMG to obtain a representative sampling of the effects of oxytocin on entire uterus. The range of values for uSI is from 0 (no oxytocin effects) to 10 (maximal oxytocin effects). Low values of uSI guide the end-user to increase the current dose of oxytocin. Intermediate values of uSI guide the end-user to hold the current dose. High values of uSI guide the end-user to decrease the current dose.
The purpose of this study is to establish the ranges of uSI values that correspond to the dosing actions increase, hold and decrease. To establish these ranges, 51 subjects will undergo current methods of dosing while having multichannel EMG recorded. uSI values will not be available to end-users, so all subjects will receive dosing actions determined by standard of care using current method. After delivery, a panel of experts will retrospectively assess each dosing action based on the outcome of the dosing action. These "optimized dosing actions" will then be correlated with the uSI value obtained at that time. This process produces paired data of optimized actions and uSI values. From the clustering of the uSI values, the ranges of uSI can be matched to the dosing actions increase, hold and decrease.
As a second goal, human factors will be studied with questionnaires and end-user interviews to improve the methods used for recording multichannel EMG during labor.
Procedure. Patients receiving oxytocin for clinical indications will be approached for participation. After obtaining consent, up to 8 proprietary EMG sensors will be placed over the subject's abdomen, spanning most of the surface of the uterus. Additionally, one ground sensor and one noise rejection sensor will be placed. Multichannel EMG recordings will be obtained throughout the labor, although the results of the EMG will not be available to the obstetrical providers. Subjects will be managed using current methods of monitoring and standard of care for oxytocin dosing decisions.
At the conclusion of the recording, the EMG sensors will be removed from the subject. Data will be analyzed after delivery, producing uSI values as a function of time for the duration of the labor.
An expert panel will be assembled, composed of clinicians trained in the art of obstetrics and managing oxytocin. The progress of labor will be assessed by examining the fetal monitor strip (i.e. uterine contractile activity and the fetal heart rate over time), cervical changes, and the dosing actions performed. No less than 72 hours after delivery the neonate's and subject's medical records will be reviewed to identify complications of the delivery that may have occurred.
The expert panel will assess each dosing action as optimal or not optimal. An example of a not optimal action would be increasing the dose and causing uterine tachysytole. In this example, "hold" will be assigned as the optimized dosing action. Each subject will have a list of optimized dosing actions and the time they were performed. Optimized dosing actions will then be linked with uSI values observed at that time, creating a paired data set of uSI values and optimal dosing actions.
The optimized dosing actions increase, hold and decrease will be correlated with uSI values and the range of uSI values that correspond with each dosing action will be established.
End-users will be interviewed 1 to 72 hours after delivery of the baby. The interview will identify barriers to EMG recording may influence the effectiveness of the information provided by the multichannel EMG recording.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- prospective, non-significant risk
| Arm | Type | Receives |
|---|---|---|
| Uterine EMG during labor | Experimental | Device: uterine electromyographyMultichannel uterine electromyography will be recorded on patients receiving oxytocin for induction or augmenation of labor. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Age 18 or greater
- At least 37 weeks gestation
- English reading and speaking
- Female gender
- Singleton fetus
Key exclusion criteria (11 listed)
- Non-English reading and/or speaking
- Twins, triplets and other multifetal gestations
- Non-vertex presentation
- Planned Cesarean delivery
- Significant uterine anomalies such as didelphys or bicornuate uterus (women with small, clinically insignificant anomalies such as uterine fibroids are not excluded).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| uterine electromyographyAlso: electrohysterographyMultichannel uterine electromyography will record uterine biosignals during labor. | Device | Uterine EMG during labor |
Primary outcome
Correlating uSI with the optimized dosing actions increase, hold and decrease
Time frame: 8 months
uSI clustering with dosing actions will be identified to provide guidance when prospectively dosing oxytocin
Human factors in recording multichannel EMG during labor
Time frame: 8 months
Difficulties and discomfort of the EMG recording process will be identified and corrected
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2020.
- Individual participant dataSharing planned: No. No IPD will be shared with other researchers. Data in summary form, based on numerical assessments of the uSI and optimized dosing actions will be published.
Related trials for Pregnancy Related
Recruiting
Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure
Neonatal Respiratory Distress Related Conditions, Meconium
Not yet recruitingObservational study
Microbiota Changes Related to Outcomes in Kidney Transplantation
End-stage Renal Disease (ESRD), Kidney Transplantation
RecruitingObservational study
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
Pregnancy Related
Not yet recruitingObservational study
Novel Antimicrobial Solution to Prevent Infections
Kidney Stone, Infection
Not yet recruitingObservational study
Early Nutrition and Heart Structure and Function in Preterm Infants During the First Year of Life
Cardiac Abnormalities, Nutrient Intake
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing uterine electromyography in people with Pregnancy Related and Labor Long, run by PreTeL, Inc at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Roger C Young, MD (16033598870, ryoung@pretelhealth.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlating uSI with the optimized dosing actions increase, hold and decrease (time frame: 8 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2020.